Publication | Closed Access

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)

MedicineMetronomic TherapyPharmacologySolid TumoursPharmacokinetic StudyNovel SulfonamidePharmacotherapyCancer TreatmentOncologyRadiation OncologyCancer Research